Pegrizeprument

N/A

Report date: 2026/04/30 17:56:16
First In Class

Base Information

Drug NamePegrizeprument
Drug Alias NameAnti-CD28 pegylated monoclonal antibody fragmentFR-104JNJ-3133VEL-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionT lymphocytes inhibitorsT-cell-specific surface glycoprotein CD28 antagonists
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsRejection of renal transplantationPostoperative ComplicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEffimune
China Registration ClassN/A

Develop Information

Active CompaniesVeloxis PharmaceuticalsOse Immunotherapeutics
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsPostoperative ComplicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A